Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Posted by Renee Jackson on Mar 18th, 2025

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Free Report) was the target of a large drop in short interest in February. As of February 28th, there was short interest totalling 1,980,000 shares, a drop of 21.4% from the February 13th total of 2,520,000 shares. Based on an average trading volume of 5,940,000 shares, the short-interest ratio is presently 0.3 days. Approximately 4.2% of the shares of the company are short sold.

Institutional Trading of Cardio Diagnostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CDIO. Two Sigma Securities LLC bought a new stake in shares of Cardio Diagnostics in the fourth quarter valued at approximately $48,000. Jane Street Group LLC bought a new stake in Cardio Diagnostics in the 4th quarter valued at $103,000. Millennium Management LLC acquired a new stake in Cardio Diagnostics in the 4th quarter worth $236,000. Finally, Geode Capital Management LLC increased its holdings in shares of Cardio Diagnostics by 97.6% during the 4th quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock worth $334,000 after purchasing an additional 179,978 shares during the period. Institutional investors and hedge funds own 8.06% of the company’s stock.

Cardio Diagnostics Stock Performance

NASDAQ:CDIO traded down $0.02 during midday trading on Tuesday, reaching $0.44. The stock had a trading volume of 397,423 shares, compared to its average volume of 2,510,117. Cardio Diagnostics has a 1-year low of $0.19 and a 1-year high of $1.77. The firm’s fifty day simple moving average is $0.52 and its 200-day simple moving average is $0.47.

About Cardio Diagnostics

(Get Free Report)

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.